• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ITGB3 促进骨肉瘤肿瘤对顺铂的耐药性。

ITGB3 promotes cisplatin resistance in osteosarcoma tumors.

机构信息

The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, P.R. China.

出版信息

Cancer Med. 2023 Apr;12(7):8452-8463. doi: 10.1002/cam4.5585. Epub 2023 Feb 11.

DOI:10.1002/cam4.5585
PMID:36772869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10134362/
Abstract

OBJECTIVE

Osteosarcoma is the most malignant and common primary bone tumor with a high rate of recurrence that mainly occurs in children and young adults. Therefore, it is vital to facilitate the development of novel effective therapeutic means and improve the overall prognosis of osteosarcoma patients via a deeper understanding of the mechanisms of chemoresistance in osteosarcoma progression.

METHODS

In this research, the relationship between ITGB3 and the clinical characteristics of patients was detected through analysis of publicly available clinical datasets. The expression of ITGB3 was analysis in collected human osteosarcoma tissues. In addition, the potential functions of ITGB3 in the cisplatin resistance of osteosarcoma cells were investigated in vitro and in tumor xenotransplantation. Finally, the molecular mechanism of ITGB3 in the progression and recurrence of osteosarcoma were explored via transcriptome analysis.

RESULTS

ITGB3 was identified as a potential regulator of tumorigenicity and cisplatin resistance in relapsed osteosarcoma. Furthermore, the decreased osteosarcoma cell proliferation and migration ability in ITGB3 knockout osteosarcoma cells were related to increased apoptosis and slowing cell cycle progression. In addition, ITGB3 had a positive correlation with cisplatin resistance in cells and tumor xenografts in mice. Accordingly, ITGB3 performed the functions of proliferation and cisplatin resistance in osteosarcoma through the MAPK and VEGF signaling pathways.

CONCLUSION

Our results will contribute to a better understanding of the function and mechanism of ITGB3 in osteosarcoma cisplatin resistance and provide a novel therapeutic target to decrease cisplatin resistance and tumor recurrence in osteosarcoma patients.

摘要

目的

骨肉瘤是最恶性和最常见的原发性骨肿瘤，其复发率高，主要发生在儿童和青少年。因此，深入了解骨肉瘤进展中化疗耐药的机制，对于开发新的有效治疗手段和改善骨肉瘤患者的整体预后至关重要。

方法

在这项研究中，通过分析公共可用的临床数据集，检测了 ITGB3 与患者临床特征之间的关系。分析了收集的人骨肉瘤组织中 ITGB3 的表达。此外，还在体外和肿瘤异种移植中研究了 ITGB3 对骨肉瘤细胞顺铂耐药性的潜在作用。最后，通过转录组分析探讨了 ITGB3 在骨肉瘤进展和复发中的分子机制。

结果

ITGB3 被鉴定为复发性骨肉瘤中肿瘤发生和顺铂耐药的潜在调节剂。此外，ITGB3 敲除骨肉瘤细胞中的增殖和迁移能力下降与凋亡增加和细胞周期进程减缓有关。此外，ITGB3 与细胞和顺铂耐药性以及小鼠肿瘤异种移植中的顺铂耐药性呈正相关。因此，ITGB3 通过 MAPK 和 VEGF 信号通路在骨肉瘤中发挥增殖和顺铂耐药的功能。

结论

我们的研究结果将有助于更好地理解 ITGB3 在骨肉瘤顺铂耐药中的功能和机制，并为降低骨肉瘤患者的顺铂耐药性和肿瘤复发提供新的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/e8feae96ea42/CAM4-12-8452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/af58e5f83f55/CAM4-12-8452-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/adbd7b55dc2f/CAM4-12-8452-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/b87e6ffe7d8e/CAM4-12-8452-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/7a87afb7fdb5/CAM4-12-8452-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/e8feae96ea42/CAM4-12-8452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/af58e5f83f55/CAM4-12-8452-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/adbd7b55dc2f/CAM4-12-8452-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/b87e6ffe7d8e/CAM4-12-8452-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/7a87afb7fdb5/CAM4-12-8452-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27ea/10134362/e8feae96ea42/CAM4-12-8452-g001.jpg

相似文献

1
ITGB3 promotes cisplatin resistance in osteosarcoma tumors.ITGB3 促进骨肉瘤肿瘤对顺铂的耐药性。
Cancer Med. 2023 Apr;12(7):8452-8463. doi: 10.1002/cam4.5585. Epub 2023 Feb 11.
2
CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.CCN2增强人骨肉瘤对顺铂介导的细胞凋亡的抗性。
PLoS One. 2014 Mar 17;9(3):e90159. doi: 10.1371/journal.pone.0090159. eCollection 2014.
3
miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.miR-33a在化疗耐药的骨肉瘤中上调，并通过下调TWIST促进骨肉瘤细胞对顺铂的耐药性。
J Exp Clin Cancer Res. 2014 Jan 27;33(1):12. doi: 10.1186/1756-9966-33-12.
4
LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.长链非编码 RNA-SARCC 通过靶向己糖激酶 2 抑制 miR-143 介导的糖酵解来增强骨肉瘤对顺铂的敏感性。
Cancer Biomark. 2020;28(2):231-246. doi: 10.3233/CBM-191181.
5
MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.MicroRNA-22 调控骨肉瘤顺铂耐药中的自噬和凋亡。
Mol Med Rep. 2020 Nov;22(5):3911-3921. doi: 10.3892/mmr.2020.11447. Epub 2020 Aug 20.
6
Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.抑制 CHD1L 可降低骨肉瘤的增殖和耐药性。
Biochem Biophys Res Commun. 2021 May 21;554:214-221. doi: 10.1016/j.bbrc.2020.12.109. Epub 2021 Apr 1.
7
MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.微小 RNA-221 通过 PI3K/Akt 通路诱导人骨肉瘤细胞存活和顺铂耐药。
PLoS One. 2013;8(1):e53906. doi: 10.1371/journal.pone.0053906. Epub 2013 Jan 23.
8
Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.使用 DAPT（γ-分泌酶抑制剂）抑制 Notch 通路可增强顺铂在耐药性骨肉瘤中的抗肿瘤作用。
Mol Carcinog. 2019 Jan;58(1):3-18. doi: 10.1002/mc.22873. Epub 2018 Nov 5.
9
Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.长链非编码 RNA LINC00161 通过调控 miR-645-IFIT2 轴使骨肉瘤细胞对顺铂诱导的细胞凋亡敏感。
Cancer Lett. 2016 Nov 28;382(2):137-146. doi: 10.1016/j.canlet.2016.08.024. Epub 2016 Sep 5.
10
Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.增强的Stim1表达与骨肉瘤细胞中顺铂获得性化疗耐药相关。
Hum Cell. 2017 Jul;30(3):216-225. doi: 10.1007/s13577-017-0167-9. Epub 2017 Mar 22.

引用本文的文献

1
Yin Yang 1 protein-activated N-acetyltransferase 10 drives cell malignant progression of osteosarcoma through ac4C acetylation of integrin β3.阴阳1蛋白激活的N-乙酰转移酶10通过整合素β3的ac4C乙酰化驱动骨肉瘤细胞的恶性进展。
J Bone Oncol. 2025 Jul 12;53:100701. doi: 10.1016/j.jbo.2025.100701. eCollection 2025 Aug.
2
Endometriosis: An Immunologist's Perspective.子宫内膜异位症：免疫学家的观点。
Int J Mol Sci. 2025 May 28;26(11):5193. doi: 10.3390/ijms26115193.
3
Enhancing radiosensitivity of osteosarcoma by ITGB3 knockdown: a mechanism linked to enhanced osteogenic differentiation status through JNK/c-JUN/RUNX2 pathway activation.

本文引用的文献

1
7-Epitaxol induces apoptosis in cisplatin-resistant head and neck squamous cell carcinoma via suppression of AKT and MAPK signalling.7-表紫杉醇通过抑制 AKT 和 MAPK 信号通路诱导顺铂耐药的头颈部鳞状细胞癌细胞凋亡。
J Cell Mol Med. 2022 Dec;26(23):5807-5819. doi: 10.1111/jcmm.17602. Epub 2022 Oct 29.
2
The Osteosarcoma Stem Cell Activity of a Gallium(III)-Phenanthroline Complex Appended to Salicylate.含水杨酸盐的镓（III）-菲咯啉配合物的骨肉瘤干细胞活性。
Chembiochem. 2022 Dec 16;23(24):e202200532. doi: 10.1002/cbic.202200532. Epub 2022 Nov 18.
3
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
通过敲低整合素β3（ITGB3）增强骨肉瘤的放射敏感性：一种通过JNK/c-JUN/RUNX2途径激活与增强成骨分化状态相关的机制。
J Exp Clin Cancer Res. 2025 May 24;44(1):159. doi: 10.1186/s13046-025-03417-4.
4
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications.整合素在癌症耐药性中的作用：分子机制与临床意义
Int J Mol Sci. 2025 Mar 28;26(7):3143. doi: 10.3390/ijms26073143.
5
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.表皮生长因子受体（EGFR）表达的肿瘤内异质性介导了靶向治疗耐药性和药物耐受微环境的形成。
Nat Commun. 2025 Jan 2;16(1):28. doi: 10.1038/s41467-024-55378-5.
6
Identification of the biological functions and chemo-therapeutic responses of ITGB superfamily in ovarian cancer.整合素（ITGB）超家族在卵巢癌中的生物学功能及化疗反应鉴定
Discov Oncol. 2024 May 30;15(1):198. doi: 10.1007/s12672-024-01047-4.
7
Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1α/HK2 and SLC7A11 pathway.羟基红花黄色素 A 通过 HIF-1α/HK2 和 SLC7A11 通路诱导骨肉瘤癌细胞铁死亡。
Oncol Res. 2024 Apr 23;32(5):899-910. doi: 10.32604/or.2023.042604. eCollection 2024.
8
ITCH-Mediated Ubiquitylation of ITGB3 Promotes Cell Proliferation and Invasion of Ectopic Endometrial Stromal Cells in Ovarian Endometriosis.瘙痒介导的整合素β3泛素化促进卵巢子宫内膜异位症中异位子宫内膜间质细胞的增殖和侵袭。
Biomedicines. 2023 Sep 11;11(9):2506. doi: 10.3390/biomedicines11092506.
9
Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies.骨肉瘤中信号通路的靶向治疗：机制与临床研究
MedComm (2020). 2023 Jul 10;4(4):e308. doi: 10.1002/mco2.308. eCollection 2023 Aug.
卡博替尼靶向 c-MET 和 AXL 可能成为头颈部鳞癌细胞癌患者的一种潜在治疗策略。
Cell Rep Med. 2022 Sep 20;3(9):100659. doi: 10.1016/j.xcrm.2022.100659.
4
linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer.linc00958/miR-185-5p/RSF-1 通过 AKT1/GSK3β/VEGFA 通路调节宫颈癌顺铂耐药和血管生成。
Reprod Biol Endocrinol. 2022 Sep 2;20(1):132. doi: 10.1186/s12958-022-00995-2.
5
Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway.青蒿素 B 通过调节连接蛋白 43 和 MAPK 通路增强顺铂治疗非小细胞肺癌的疗效。
Am J Chin Med. 2022;50(7):1963-1992. doi: 10.1142/S0192415X22500847. Epub 2022 Aug 31.
6
Interfering with ITGB1-DT expression delays cancer progression and promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.干扰ITGB1-DT表达可通过抑制MAPK/ERK途径延缓癌症进展并提高非小细胞肺癌对顺铂的细胞敏感性。
Am J Cancer Res. 2022 Jul 15;12(7):2966-2988. eCollection 2022.
7
Resolvin E1 Reduces Tumor Growth in a Xenograft Model of Lung Cancer.解析 E1 可减少肺癌移植瘤模型中的肿瘤生长。
Am J Pathol. 2022 Oct;192(10):1470-1484. doi: 10.1016/j.ajpath.2022.07.004. Epub 2022 Aug 6.
8
Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models.在 SMAD4 阴性食管腺癌中选择性靶向 BMP2 和 4 可抑制临床前模型中的肿瘤生长和侵袭性。
Cell Oncol (Dordr). 2022 Aug;45(4):639-658. doi: 10.1007/s13402-022-00689-2. Epub 2022 Jul 28.
9
FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.FOXP1 通过抑制 P53 下游的 P21 和 RB 转录来驱动骨肉瘤的发展。
Oncogene. 2021 Apr;40(15):2785-2802. doi: 10.1038/s41388-021-01742-4. Epub 2021 Mar 14.
10
Identification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis.与骨肉瘤转移相关的三个关键预后基因的鉴定与分析
J Oncol. 2021 Jan 30;2021:6646459. doi: 10.1155/2021/6646459. eCollection 2021.